ATE350036T1 - Tetrahydroquinolin-derivate - Google Patents

Tetrahydroquinolin-derivate

Info

Publication number
ATE350036T1
ATE350036T1 AT00964738T AT00964738T ATE350036T1 AT E350036 T1 ATE350036 T1 AT E350036T1 AT 00964738 T AT00964738 T AT 00964738T AT 00964738 T AT00964738 T AT 00964738T AT E350036 T1 ATE350036 T1 AT E350036T1
Authority
AT
Austria
Prior art keywords
tetrahydroquinoline derivatives
derivatives
salts
tetrahydroquinoline
agonism
Prior art date
Application number
AT00964738T
Other languages
English (en)
Inventor
Keigo Hanada
Original Assignee
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd filed Critical Kaken Pharma Co Ltd
Application granted granted Critical
Publication of ATE350036T1 publication Critical patent/ATE350036T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00964738T 1999-10-14 2000-10-06 Tetrahydroquinolin-derivate ATE350036T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29202199 1999-10-14

Publications (1)

Publication Number Publication Date
ATE350036T1 true ATE350036T1 (de) 2007-01-15

Family

ID=17776517

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964738T ATE350036T1 (de) 1999-10-14 2000-10-06 Tetrahydroquinolin-derivate

Country Status (10)

Country Link
US (1) US7037919B1 (de)
EP (1) EP1221439B1 (de)
KR (2) KR100731566B1 (de)
CN (1) CN1157379C (de)
AT (1) ATE350036T1 (de)
AU (1) AU7558900A (de)
CA (1) CA2387201C (de)
DE (1) DE60032780T2 (de)
ES (1) ES2277853T3 (de)
WO (1) WO2001027086A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
EP1520856A4 (de) * 2002-06-19 2010-01-13 Kaken Pharma Co Ltd Androgenrezeptorantagonist
WO2004013104A1 (ja) * 2002-08-01 2004-02-12 Kaken Pharmaceutical Co., Ltd. 新規テトラヒドロキノリン誘導体
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US7011600B2 (en) 2003-02-28 2006-03-14 Fallbrook Technologies Inc. Continuously variable transmission
BRPI0413820A (pt) 2003-08-22 2006-10-24 Ligand Pharm Inc derivados de 6-cicloamino-2-quinolinona como compostos moduladores de receptor de androgênio
DK1761515T3 (da) * 2003-12-20 2009-02-16 Merck Patent Gmbh 2-(hetero-)aryl-substituerede tetrahydroquinolinderivater
SE0400285D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
BRPI0608553A2 (pt) 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias
NZ560354A (en) * 2005-06-17 2010-10-29 Ligand Pharm Inc Androgen receptor modulator compounds and methods
KR101831822B1 (ko) 2005-10-28 2018-02-23 폴브룩 인텔렉츄얼 프로퍼티 컴퍼니 엘엘씨 전동 드라이브
EP1954959B1 (de) 2005-11-22 2013-05-15 Fallbrook Intellectual Property Company LLC Stufenlos verstellbares getriebe
CN100376582C (zh) * 2006-04-26 2008-03-26 浙江大学 一种六氢呋喃[3,2-c]喹啉衍生物的制备方法
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
UA98777C2 (en) * 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
WO2008095116A2 (en) 2007-02-01 2008-08-07 Fallbrook Technologies, Inc. System and methods for control of transmission and/or prime mover
WO2008101070A2 (en) 2007-02-16 2008-08-21 Fallbrook Technologies Inc. Infinitely variable transmissions, continuously variable transmissions, methods, assemblies, subassemblies, and components therefor
EP2573425A3 (de) 2007-04-24 2017-07-26 Fallbrook Intellectual Property Company LLC Elektrische Fahrantriebe
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
JP5783723B2 (ja) 2007-12-21 2015-09-24 フォールブルック インテレクチュアル プロパティー カンパニー エルエルシー 自動変速機及びその方法
CA2942806C (en) 2008-02-29 2018-10-23 Fallbrook Intellectual Property Company Llc Continuously and/or infinitely variable transmissions and methods therefor
JP5599385B2 (ja) * 2008-04-24 2014-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲンレセプターの小分子阻害剤
CN107246463A (zh) 2008-06-23 2017-10-13 福博科知识产权有限责任公司 无级变速器
CA2732668C (en) 2008-08-05 2017-11-14 Fallbrook Technologies Inc. Methods for control of transmission and prime mover
US8167759B2 (en) 2008-10-14 2012-05-01 Fallbrook Technologies Inc. Continuously variable transmission
WO2010120933A1 (en) 2009-04-16 2010-10-21 Fallbrook Technologies Inc. Stator assembly and shifting mechanism for a continuously variable transmission
US8512195B2 (en) 2010-03-03 2013-08-20 Fallbrook Intellectual Property Company Llc Infinitely variable transmissions, continuously variable transmissions, methods, assemblies, subassemblies, and components therefor
US8888643B2 (en) 2010-11-10 2014-11-18 Fallbrook Intellectual Property Company Llc Continuously variable transmission
PH12013502619A1 (en) 2011-06-17 2014-02-17 Merck Sharp & Dohme Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
EP3733170A1 (de) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. Verfahren zur behandlung von androgenrezeptor(ar)-positivem brustkrebs mit selektivem androgenrezeptormodulator (sarms)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US12685719B2 (en) 2012-07-13 2026-07-21 University Of Tennessee Research Foundation Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
CN105017266B (zh) * 2015-07-17 2017-07-18 安徽农业大学 手性2‑芳基‑1,2,3,4‑四氢喹啉类化合物及其合成方法
BR112020023136A2 (pt) 2018-05-14 2021-02-09 Nuvation Bio Inc. compostos de alvo de receptor de hormônio nuclear anticâncer
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
EP4058464A1 (de) 2019-11-13 2022-09-21 Nuvation Bio Inc. Auf nuklearhormonrezeptor abzielende antikrebsverbindungen
CN116096367A (zh) * 2020-06-08 2023-05-09 苏黎世大学 Frs2–fgfr相互作用的小分子抑制剂及其在医学、在预防和治疗癌症中的用途
EP4313991A1 (de) 2021-03-23 2024-02-07 Nuvation Bio Inc. Gegen krebs gerichtete kernhormonrezeptorverbindungen
WO2022235585A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN116969959B (zh) * 2023-08-03 2025-10-31 浙江大学 取代四氢喹啉类衍生物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2500441A1 (fr) * 1981-02-23 1982-08-27 Roussel Uclaf Nouveaux medicaments derives de la 3-hydroxy dodecahydro benz (e) inden-7-one, produits derives de la 3-hydroxy dodecahydro benz (e) inden-7-one et leur procede de preparation
US5288725A (en) 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
AU717251B2 (en) * 1994-12-22 2000-03-23 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5925527A (en) * 1997-02-04 1999-07-20 Trega Biosciences, Inc. Tricyclic Tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries

Also Published As

Publication number Publication date
EP1221439B1 (de) 2007-01-03
KR100731566B1 (ko) 2007-06-22
KR100826485B1 (ko) 2008-05-02
US7037919B1 (en) 2006-05-02
KR20020056901A (ko) 2002-07-10
DE60032780D1 (de) 2007-02-15
EP1221439A4 (de) 2003-01-15
ES2277853T3 (es) 2007-08-01
CN1378535A (zh) 2002-11-06
CA2387201C (en) 2009-05-26
CN1157379C (zh) 2004-07-14
AU7558900A (en) 2001-04-23
WO2001027086A1 (en) 2001-04-19
DE60032780T2 (de) 2007-11-08
EP1221439A1 (de) 2002-07-10
KR20070036192A (ko) 2007-04-02
CA2387201A1 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
DE60032780D1 (de) Tetrahydroquinolin-derivate
DK0778277T3 (da) Substituerede heterocycliske derivater som CRF antagonister
ES2182234T3 (es) Inhibidores de metaloproteasa.
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
PT911333E (pt) Derivados de pirazolo¬4,3-d|pirimidina e composicoes farmaceuticas que os contenham
MY136141A (en) Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
DE69820248D1 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
FI902555A0 (fi) Diarylstyrylkinolindisyror.
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
ATE278661T1 (de) Anthranilsäurederivate
BR0109542A (pt) Derivados de imidazopirina alquilados
ES2166046T3 (es) Derivados de arilacrilamida como agonistas o antagonistas de 5ht1.
PT882726E (pt) Carbazol-carboxamidas como agonistas 5-ht1f
BR0209901A (pt) Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina
NO20002408D0 (no) 5-HT1F antagonister
FI952420A0 (fi) Glukopyranosidibentsotiofeenit
CA2423357A1 (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors
BR9902096A (pt) Pitazóis.
DK0625520T3 (da) Thiazolotriazol- og thiazolodiazolderivater med fungicid aktivitet
IL160162A0 (en) Salts of substituted 1,2,3,4,-tetrahydroisoquinolie-2-carboxylic acid derivatives
FI20000421A0 (fi) Nukleotidejä sisältävien yhdisteiden kuljetukseen käyttökelpoisia 1,4-Dihydropyridiinijohdannaisia
EP1118327A4 (de) Vorbeugende und/oder therapeutische mittel zur behandlung der sinusitis.
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties